Acadia Pharmaceuticals appoints Scott Cenci as Chief Information and Data Officer.

Acadia Pharmaceuticals has appointed Scott Cenci as Chief Information and Data Officer. Cenci brings over 25 years of experience in the pharmaceutical and biotechnology industries, having held senior leadership roles at Genmab, Biogen, Zoetis, and Pfizer. He will lead Acadia's digital transformation, including technology, data, and AI strategy, and serve as a member of the company's Executive Leadership Team.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has appointed Scott Cenci as Senior Vice President, Chief Information and Data Officer. Cenci brings over 25 years of experience in the pharmaceutical and biotechnology industries, having held senior leadership roles at Genmab, Biogen, Zoetis, and Pfizer. He will lead Acadia's digital transformation, including technology, data, and AI strategy, and serve as a member of the company's Executive Leadership Team [1].

Scott Cenci's extensive background includes leading enterprise-wide digital and AI initiatives, implementing global ERP and cloud platforms, and driving operational efficiencies through agile methodologies and data analytics. He has played key roles in major corporate transformations, including IPOs, spin-offs, and M&A integrations. Most recently, he served as Senior Vice President of Global Information Technology and Digital at Genmab, where he transformed the IT function into a full-scale digital organization, supporting the company's growth from 500 to 2,700 employees and from $750 million to over $3 billion in revenue [1].

Cenci holds an MBA in Management Information Systems from Seton Hall University and a BS in Computer Science and a minor in Mathematics from The College of New Jersey. He has served as an advisor to professional organizations and is an active member of the Osage Venture Partners Technology Advisory Board. Additionally, Cenci has served as a speaker on topics such as Generative AI and digital transformation [1].

Acadia Pharmaceuticals is a leader in advancing breakthroughs in neurological and rare diseases. The company's clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis, and multiple other programs targeting neuroscience and neuro-rare diseases. The appointment of Scott Cenci underscores Acadia's commitment to leveraging technology and data to accelerate innovation and improve patient care [2].

References:
[1] https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-appoints-scott-cenci-as-chief-information-and-ir1lyq02xcja.html
[2] https://acadia.com/en-us/careers/job-board/8096731002